BioInvent - translating cancer antibody biology into innovative immuno-oncology therapies.
Based on its cutting-edge insights in immunology, cancer biology and antibody biology, BioInvent develops immunotherapies to improve and prolong cancer patients’ lives. The company strives for excellence in drug development to create better health for cancer patients and significant value for our shareholders.
BioInvent's current operational activities are focused on:
- Progressing and expanding the clinical development of its lead antibody BI-1206 for treatment of haematological cancers.
- Developing pre-clinical first-in-class antibodies targeting tumour-associated myeloid cells in collaboration with Pfizer.
- Advancing its innovative pre-clinical Treg immuno-oncology programmes identifying antibodies to novel targets and pathways, as well as differentiated antibodies with new mechanisms-of-action to validated targets.
- Ensure an expeditious start of the new collaboration with Transgene to develop oncolytic virus (OV) candidates encoding a validated anti-CTLA-4 antibody sequence - potentially with additional transgenes - capable of treating multiple solid tumours.
- Developing TB-403, in collaboration with Oncurious, as a potential treatment for paediatric brain cancers.
- Generating further revenues through antibody contract manufacturing and technology deals.
Immuno-oncology drugs can revolutionise treatment of cancer
The body’s immune system detects and destroys bacteria and viruses that would otherwise harm our organs and tissues. However, the immune system also has the potential to protect us from and fight cancer. Unfortunately, many tumour cells have the ability to manipulate important cells in our immune system in order to continue to multiply.
While chemotherapy is aimed directly at the tumour cells, immuno-oncology drugs activate important cells in the immune system (especially T-cells), and stimulate them to attack tumours. Immuno-oncology drugs are one of the greatest breakthroughs of the twenty-first century in the field of medicine.
They are making an important contribution in transforming the treatment of cancer through significant improvements in survival rates. However currently available immune modulatory drugs are only able to help a fraction of all cancer patients. Commercially, immuno-oncology therapies are expected to continue to be a success, with estimated sales to exceed USD 40 billion by 2022, according to the Cowen 2017 Therapeutic Categories report.
A special type of molecule known as checkpoints can be found on the surface of our white blood cells. Checkpoints function as a kind of switch to activate or deactivate the immune system. In some cases cancer cells manipulate these proteins to avoid attacks. For the past few years, immuno-oncology drugs have been used that are capable of inhibiting the checkpoint receptors PD-1, PD-L1 and CTLA-4. They have produced good treatment in certain types of solid tumours and achieved great commercial success, but unfortunately they only help a minority of patients with metastatic cancer. Consequently, intense efforts are underway to develop new drugs that can complement the checkpoint inhibitors in order to improve survival.
BioInvent strives to contribute to the development of more effective cancer treatments. The Company occupies a prominent position within the understanding of the biological and immunological aspects of cancer treatment and has a unique platform for identifying and developing new types of antibodies against the relevant target structures.
BioInvent is developing antibodies specific for regulatory T-cells and tumour-associated myeloid cells, both of which are expected to have synergies in combination with currently available checkpoint inhibitors.
Five focus areas for our value creation
BioInvent’s strategy is to leverage its expertise in antibodies and cancer biology to develop immuno-oncology drugs that significantly improve the treatment of cancer diseases and prolong cancer patients' lives. This is accomplished through collaborations with large pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
Five focus areas are deemed essential to the Company’s continued success – high-level science, professional product development, commercial focus, sound risk management and financing.